Abstract: The present invention provides untargeted and targeted IL-10-Fc fusion proteins, compositions and methods of use thereof. The targeted IL-10-Fc fusion proteins includes those that bind PD-1, TIGIT, CD8 and NKG2D.

Abstract: A build plate assembly for a three-dimensional printer includes: a lighting panel having individually addressable pixels configured to selectively emit light and/or transmit light from illumination below the pixels to a top surface top surface of the lighting panel; a rigid, optically transparent, gas-impermeable planar screen or base having an upper surface having an uneven surface topology and a lower surface that is affixed to the top surface of the lighting panel; and a flexible, optically transparent, gas-permeable sheet having upper and lower surfaces, the upper surface comprising a build surface for forming a three-dimensional object, the sheet lower surface positioned opposite the base, wherein the build plate is configured to permit gas flow to the build surface.

Abstract: Provided herein are variant human IL18 proteins including proteins and constructs including such. Various variant IL18 proteins with modifications to reduce heterogeneity and/or reduce affinity/potency and/or improve stability and/or improve production yield are also described. Also provided are IL18-Fc fusion proteins that include an empty-Fc domain and an IL18 protein connected to another Fc domain. Also provided herein are IL18Fc fusion proteins that bind CD3 and a tumor target antigen.

Abstract: A modular expansion joint system with equidistance control. The modular expansion joint system includes transverse vehicle load bearing members which are positioned in a gap defined between adjacent spaced-apart structural members, support members positioned below the transverse vehicle load bearing members and extending across the expansion joint gap between the adjacent structural members, means positioned within the structural members for controlling movement of the support members, and means for controlling the spacing between the transverse vehicle load bearing members. The means for controlling the distance between the transverse vehicle load bearing members comprises a non-elastomeric compressive member, such as at least one coil spring which, which according to certain illustrative embodiments, maintains a substantially equal distance between transverse vehicle load bearing members.

Abstract: A modular expansion joint system with equidistance control. The modular expansion joint system includes transverse vehicle load bearing members which are positioned in a gap defined between adjacent spaced-apart structural members, support members positioned below the transverse vehicle load bearing members and extending across the expansion joint gap between the adjacent structural members, means positioned within the structural members for controlling movement of the support members, and means for controlling the spacing between the transverse vehicle load bearing members. The means for controlling the distance between the transverse vehicle load bearing members comprises a non-elastomeric compressive member, such as at least one coil spring which, which according to certain illustrative embodiments, maintains a substantially equal distance between transverse vehicle load bearing members.

Abstract: An expansion joint system for bridging a gap between spaced apart structural members and capable of self-cleaning. The expansion joint system includes first and second base members, at least one upwardly sloped base plate engaged with one of the first and second base members, and at least one substantially horizontal movable plate engaged with at least one of the first and second base members. Also disclosed is an expansion joint including a first structural member and a second structural member, first and second base members, at least one upwardly sloped base plate engaged with one of the first and second base members, and at least one substantially horizontal movable plate engaged with at least one of the first and second base members.

Abstract: The present invention is directed to novel heterodimeric antibodies.

Abstract: In one aspect, the present invention provides heterodimeric antibodies comprising a first monomer comprising a first heavy chain constant domain comprising a first variant Fc domain and a first antigen binding domain and a second monomer comprising a second heavy chain constant domain comprising a second variant Fc domain and a second antigen binding domain. In an additional aspect the heterodimeric antibody comprises a first monomer comprising a heavy chain comprising a first Fc domain and a single chain Fv region (scFv) that binds a first antigen, wherein the scFv comprises a charged scFv linker. The heterodimeric antibody further comprises a second monomer comprising a first heavy chain comprising a second Fc domain and a first variable heavy chain and a first light chain.

Abstract: A mobile device with a route prediction engine is provided that can predict current/future destinations or routes to destinations for the user, and can relay prediction information to the user. The engine includes a machine-learning engine that facilitates the formulation of predicted future destinations and/or future routes to destinations based on user-specific data. The user-specific data includes data about (1) previous destinations traveled, (2) previous routes taken, (3) locations of calendared events, (4) locations of events for which the user has electronic tickets, and/or (5) addresses parsed from e-mails and/or messages. The prediction engine relies on one or more of user-specific data stored on the device and data stored outside of the device by external devices/servers.

Abstract: Provided herein are novel anti-CD28×anti-B7H3 (also referred to as “?CD28×?B7H3”) heterodimeric bispecific antibodies and methods of using such antibodies for the treatment of cancers. Subject ?CD28×?B7H3 antibodies are capable of agonistically binding to CD28 costimulatory molecules on T cells and targeting to B7H3 on tumor cells. Thus, such antibodies selectively enhance anti-tumor activity at tumor sites while minimizing peripheral toxicity. The subject antibodies provided herein are particularly useful for enhancing anti-tumor activity when used in combination with other anti-cancer therapies.

Abstract: Provided herein are novel anti-CD28 x anti-TROP2 antibodies and methods of using such antibodies for the treatment of TROP2-associated cancers. Subject anti-CD28 x anti-TROP2 antibodies are capable of agonistically binding to CD28 costimulatory molecules on T cells and TROP2 on tumor cells. Thus, such antibodies selectively enhance anti-tumor activity at tumor sites while minimizing peripheral toxicity. The subject antibodies provided herein are particularly useful in combination with other anti-cancer therapies, including, for example, bispecific antibodies for the treatment of TROP2-associated cancers.

Abstract: The present invention is directed to bispecific, heterodimeric immunomodulatory antibodies.

Abstract: The present invention provides binding agents comprising at least two binding domains, wherein a first binding domain has specificity for CLDN18.2 and a second binding domain has specificity for CD3, and methods of using these binding agents or nucleic acids encoding therefor for treating cancer.

Abstract: The present invention is directed to novel heterodimeric antibodies.

Abstract: The present invention is directed to optimized anti-CD3 variable sequences for use in a variety of bispecific formats, including those that utilize scFv components. The invention further relates to nucleic acids encoding for the polypeptide, to vectors comprising the same and to host cells comprising the vector. In another aspect, the invention provides for a pharmaceutical composition comprising the mentioned polypeptide and medical uses of the polypeptide.

Abstract: The invention provides novel heterodimeric proteins including heterodimeric antibodies.

Abstract: Provided herein are novel ?PD-L1, ?PD-L2, and ?CD28 antibodies. In some embodiments, the antibodies are ?PD-L1×?PD-L2×?CD28 antibodies. Such antibodies enhance anti-tumor activity by providing a costimulatory signal for T-cell activation against tumor cells while advantageously also blocking inhibitory PD-L1:PD1 and/or PD-L2:PD1 pathway interactions.

Abstract: The present invention is directed to novel heterodimeric antibodies.

Abstract: In one aspect, the present invention provides heterodimeric antibodies comprising a first monomer comprising a first heavy chain constant domain comprising a first variant Fc domain and a first antigen binding domain and a second monomer comprising a second heavy chain constant domain comprising a second variant Fc domain and a second antigen binding domain. In an additional aspect the heterodimeric antibody comprises a first monomer comprising a heavy chain comprising a first Fc domain and a single chain Fv region (scFv) that binds a first antigen, wherein the scFv comprises a charged scFv linker. The heterodimeric antibody further comprises a second monomer comprising a first heavy chain comprising a second Fc domain and a first variable heavy chain and a first light chain.

Abstract: Provided herein are novel anti-CD28×anti-MSLN antibodies and methods of using such antibodies for the treatment of MSLN-associated cancers. Subject anti-CD28×anti-MSLN antibodies are capable of agonistically binding to CD28 costimulatory molecules on T cells and MSLN on tumor cells. Thus, such antibodies selectively enhance anti-tumor activity at tumor sites while minimizing peripheral toxicity. The subject antibodies provided herein are particularly useful in combination with other anti-cancer therapies, including, for example, bispecific antibodies for the treatment of MSLN-associated cancers (e.g., ovarian cancers).